Sarepta gene therapy study missed key target in Duchennes, page-116

Thanks Waynesworld, as always, great summary. There is no doubt that big Pharma in the DMD space are aware of our P2 results and some are busily doing due diligence on our company. The recent Morgan's and Wilson's reports should accelerate this process as clearly both have done their homework, (derisked range $1.3 - $1.8). Now with Sarepta out of the picture, I think we can safely project a derisked share price over $2. So when the penny finally drops we should see a significant rerate to at least 50 cents prior to P2b and if it's a successful open label study, $1 by years end... time to accumulate and hold. Exciting time ahead...